What is Aspartylglucosaminuria?
Aspartylglucosaminuria or AGU for short, is an ultra-rare genetic disease belonging to a group of lysosomal storage disorders. Lysosomes are cellular compartments containing enzymes, responsible for the final (cellular) breakdown of fats, proteins and sugars. One of the lysosomal enzymes, called aspartylglucosaminidase (AGA), is necessary for breakdown of glycoproteins (proteins with a long-chain sugar attached to them). A malfunction of this enzyme leads to the physical and neurological disease manifestations in AGU.
Glycoproteins are very abundant and a necessary part of human life. Examples of glycoproteins present in a human body are antibodies (immunoglobulins), collagens (structural protein of connective tissue, transferrin (iron (Fe) transport in blood), hormones (like thyroid-stimulating hormone, alpha-fetoprotein, etc.) and many others. However, the excessive buildup of glycoproteins contributes to cellular deaths and bodily damage.
Early signs of Aspartylglucosaminuria (AGU):
Most Common Signs Seen in Children with AGU:
Articulation problems and speech/language delay;
Clumsiness or delayed/slow motor functions;
Recurring infections including ENT (ear, nose, throat) infections;
Slow healing scratches and cuts, etc.
Development of a child with Aspartylglucosaminuria
Pregnancy and infancy progress normally. AGU babies have growth spurts in the first years of their lives, so they look very healthy. Once born, girls may have umbilical and boys inguinal hernias, which are usually repaired easily by surgeons. Infections are more common in AGU toddlers compared to an average child and most AGU children get ear tubes due to continuous ear infections.
The first sign of AGU is slow speech development. The kids are more clumsy that their peers, with awkward walking or running, sometimes leaning forward. Delayed speech, attention deficit, clumsiness, restlessness, continuous respiratory infections are present in most of the preschoolers.
School age children learn material at a slower rate. Most of the AGU children start to attend special education by middle school. Some children learn how to read and write, they like to participate in sports, art and crafts.
Depending on the level of care received, children develop and continue to learn until their twenties or later. An AGU patient's life expectancy usually averages 25 -35 year of age for a male and 30-40 years of age for a female, with young adults typically dying from some sort of infection.
The disease was studied in Finland and most of the literature describes the progression of the disease in Finnish population. Cases of the disease have been reported in almost every country and affect many nations. Disease progression varies in different nationalities, with some cases reported fatal as early as 2 years old.
Aspartylglucosaminuria (AGU) is an ultra-rare disorder, currently diagnosed in ~150 patients.
Nonetheless are people diagnosed and living with AGU all over the world. Certain nationalities, including people who Finnish or Turkish descent, present increased prevalence.
Autism or Aspartylglucosaminuria or ADHD?
The initial symptoms of Aspartylglucosaminuria (AGU) are slow language development and speech delay which can be noticed as early as two years of age. School-age children are often diagnosed with ADHD or language/auditory processing disorder as they are slow to process information. Evaluators usually initially attribute AGU-linked inattentiveness or inability to process information to Autism or ADHD, which are more common disorders. As a result, all AGU kids end up being diagnosed with autism spectrum disorder and/or ADHD. They may be prescribed treatments or therapies for Autism or ADHD, which do not help AGU.
However, the reason for the Autism or ADHD-like presentation and behavior is a lack of cellular enzyme that breaks down glycoproteins. They are most abundant in the body tissues and in major organs, such as the liver, spleen, thyroid and brain. Unbroken pieces of glycoproteins accumulate in the body tissues are also excreted in urine. The process involves cumulative destruction of cell, and damage to tissues and organs, which lead to eventual death.
There is currently no approved treatment for AGU. The proper treatment for the disease is to introduce the missing enzyme back into the body. It is possible to do this with chaperone therapy or gene replacement therapy.
We need your help to start our clinical trial for a gene therapy. Please donate.